| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/24/2011 | WO2011020319A1 Fusion protein regulating plasma glucose and lipid, its preparation method and use |
| 02/24/2011 | WO2011002834A3 Compositions and methods for diagnosis and treatment of type 1 diabetes |
| 02/24/2011 | WO2010123930A3 Chemosensory receptor ligand-based therapies |
| 02/24/2011 | US20110046599 Multi-Day Delivery Of Biologically Active Substances |
| 02/24/2011 | US20110046237 Compounds with activity at estrogen receptors |
| 02/24/2011 | US20110046235 Products comprising, and uses of, decarboxylated phenolic acids derived from chlorogenic acids of coffee |
| 02/24/2011 | US20110046234 Retinaldehyde in the Treatment of Obesity, Diabetes and Other Conditions |
| 02/24/2011 | US20110046221 Therapeutic intervention to mimic the effect of caloric restriction |
| 02/24/2011 | US20110046214 Composition inhibiting sex hormone-binding globulin |
| 02/24/2011 | US20110046212 Use of oleuropein and derivatives in the treatment of type 2 diabetes mellitus and pathologies associated with protein aggregation phenomena |
| 02/24/2011 | US20110046210 Substituted thiopenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors |
| 02/24/2011 | US20110046200 Use of antisense oligonucleotides to effect translation modulation |
| 02/24/2011 | US20110046193 Deferacirox dispersible tablets |
| 02/24/2011 | US20110046188 Compositions comprising novel ppar ligands and anti-hyperlipemic agents |
| 02/24/2011 | US20110046185 Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof |
| 02/24/2011 | US20110046171 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists |
| 02/24/2011 | US20110046170 Novel pyrimidine-pyridine derivatives |
| 02/24/2011 | US20110046162 Fused cyanopyridines and the use thereof |
| 02/24/2011 | US20110046159 Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 02/24/2011 | US20110046151 Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor |
| 02/24/2011 | US20110046149 2-amino-3-sulphonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidine antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof |
| 02/24/2011 | US20110046139 Benzocycloheptane and benzoxepine derivatives |
| 02/24/2011 | US20110046134 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE |
| 02/24/2011 | US20110046133 Organic compounds |
| 02/24/2011 | US20110046132 Benzoimidazoles as prolyl hydroxylase inhibitors |
| 02/24/2011 | US20110046131 Purines as pkc-theta inhibitors |
| 02/24/2011 | US20110046122 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazines |
| 02/24/2011 | US20110046112 Novel bicyclic sulfonamide derivatives which are l-cpt1 inhibitors |
| 02/24/2011 | US20110046110 Quinolines and related analogs as sirtuin modulators |
| 02/24/2011 | US20110046109 2,4,8-trisubstituted-8h-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy |
| 02/24/2011 | US20110046105 Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof |
| 02/24/2011 | US20110046087 Pharmaceutical composition, methods for treating and uses thereof |
| 02/24/2011 | US20110046077 Process for the extraction of mangiferin and isomangiferin |
| 02/24/2011 | US20110046076 Pharmaceutical composition, methods for treating and uses thereof |
| 02/24/2011 | US20110046073 Soluble lymphotoxin-beta receptor fusion protein and methods for inhibiting lymphotoxin beta-receptor signaling |
| 02/24/2011 | US20110046055 Therapeutic agent for diabetes |
| 02/24/2011 | US20110046054 Anti diabetic protein |
| 02/24/2011 | US20110046053 Methods and compositions for oral administration of exenatide |
| 02/24/2011 | US20110046052 Excipients for Protein Stabilization |
| 02/24/2011 | US20110046051 Method and Device for Utilizing Analyte Levels to Assist in the Treatment of Diabetes |
| 02/24/2011 | US20110046050 Phenylalkylcarboxylic acid delivery agents |
| 02/24/2011 | US20110046049 Soluble, Stable Insulin-Containing Formulations with a Protamine Salt |
| 02/24/2011 | US20110046048 High protein liquid enteral nutritional composition |
| 02/24/2011 | US20110046046 Prophylactic or therapeutic composition for diabetes or obesity |
| 02/24/2011 | US20110046045 Method of treating obesity and metabolic disorders related to excess adipose tissue by administration of sFRP-5 peptide |
| 02/24/2011 | US20110045590 Calcium-influx inhibitory factor and method of isolation thereof |
| 02/24/2011 | US20110045111 Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases |
| 02/24/2011 | US20110045108 Anti-diabetic extract of honeybush |
| 02/24/2011 | US20110045106 Coffee extract |
| 02/24/2011 | US20110045090 Formulations of flibanserin |
| 02/24/2011 | US20110045077 Encapsulated pancreatic islet cell products and methods of use thereof |
| 02/24/2011 | US20110045071 Generation of a novel type of anti-inflammatory macrophages for clinical use |
| 02/24/2011 | US20110045069 Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease |
| 02/24/2011 | US20110045062 Formulation |
| 02/24/2011 | US20110045061 Gene therapy for diabetic ischemic disease |
| 02/24/2011 | US20110045029 Oral formulation for delivery of poorly absorbed drugs |
| 02/24/2011 | US20110045007 Fusion or linked proteins with extended half life |
| 02/24/2011 | US20110045002 Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| 02/24/2011 | US20110044997 Methods |
| 02/24/2011 | US20110044988 Methods of treatment using anti-mif antibodies |
| 02/24/2011 | US20110044987 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases |
| 02/24/2011 | US20110044974 Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy |
| 02/24/2011 | US20110044939 Regulatory t cells in adipose tissue |
| 02/24/2011 | US20110044901 Novel compounds |
| 02/24/2011 | CA2774891A1 Vesicular formulations |
| 02/24/2011 | CA2771445A1 Novel fxr (nr1h4) binding and activity modulating compounds |
| 02/24/2011 | CA2771257A1 Desferrioxamine-metal complexes for the treatment of immune-related disorders |
| 02/24/2011 | CA2769409A1 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes |
| 02/23/2011 | EP2287306A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 02/23/2011 | EP2287305A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 02/23/2011 | EP2287285A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 02/23/2011 | EP2287166A2 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 02/23/2011 | EP2287165A2 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 02/23/2011 | EP2287163A1 2-amino-3-sulphonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidine antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof |
| 02/23/2011 | EP2286840A2 Treatment of obesity and related diseases |
| 02/23/2011 | EP2286839A2 Treatment of obesity and related diseases |
| 02/23/2011 | EP2286838A2 Treatment of obesity and related disorders |
| 02/23/2011 | EP2286837A2 Treatment of obesity and obesity related diseases |
| 02/23/2011 | EP2286816A1 Method of treating atherosclerosis, dyslipidemias and related conditions |
| 02/23/2011 | EP2286811A1 Chemokine receptor antagonists and methods of use thereof |
| 02/23/2011 | EP2286810A1 Pharmaceutical composition for treatment of fibromyalgia |
| 02/23/2011 | EP2286793A2 Pharmaceutical formulations comprising cannabidiol |
| 02/23/2011 | EP2286675A1 Composition for promotion of bone growth and maintenance of bone health |
| 02/23/2011 | EP2285788A1 New terpenes and macrocycles |
| 02/23/2011 | EP2285786A1 Quinoxalinedione derivatives |
| 02/23/2011 | EP2285759A1 Radiolabelled mmp selective compounds |
| 02/23/2011 | EP2285410A2 Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| 02/23/2011 | EP2285399A2 Egf-a domain-mediated modulation of pcsk9 for treating lipid disorders |
| 02/23/2011 | EP2285398A2 Methods and compositions for the treatment of obesity |
| 02/23/2011 | EP2285388A1 Use of oleuropein and derivatives in the treatment of type 2 diabetes mellitus and pathologies associated with protein aggregation phenomena |
| 02/23/2011 | EP2285369A2 Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases |
| 02/23/2011 | EP2285218A2 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging |
| 02/23/2011 | EP1863570B1 A synergistically heat stable oil media having eicosa pentaenoic acid (epa) and docosa hexaenoic acid (dha) |
| 02/23/2011 | EP1654263B2 Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 02/23/2011 | EP1448550B1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity |
| 02/23/2011 | EP1268096B2 Extrusion die |
| 02/23/2011 | CN101981201A Oil producing microbes and methods of modification thereof |
| 02/23/2011 | CN101981027A Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
| 02/23/2011 | CN101981026A Derivatives of tetrahydroquinoxaline urea, preparation thereof and therapeutic application thereof |
| 02/23/2011 | CN101981025A Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |